Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Triple Negative Breast Neoplasms 11Breast Neoplasms 11Carcinoma, Transitional Cell 9Small Cell Lung Carcinoma 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Neoplasm Metastasis 6Melanoma 6Colorectal Neoplasms 6Lung Neoplasms 5Recurrence 4Neoplasms 4Urinary Bladder Neoplasms 3Lymphoma, B-Cell 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Solid Tumor 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Merkel Cell 2Brain Neoplasms 2Advanced Solid Tumor 2Urologic Neoplasms 1

Interventions

sargramostim 1sapanisertib 1pazopanib 1itacitinib 1fludarabine 1drozitumab 1baricitinib 1atezolizumab 1Trabectedin 1Ramucirumab 1Ipilimumab 1Interferon-gamma 1INCB039110 1Gemcitabine 1Doxorubicin 1Docetaxel 1Dehydroepiandrosterone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sarcoma, Synovial × atezolizumab × Clear all
NCT02609984 2020-07-07

IMDZ-C232

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Terminated
89 enrolled 24 charts
Sarcoma

Liposarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡